Telix Pharmaceuticals Limited is hiring a
Director of Targeted Alpha Therapy Research

Summary

Join Telix Pharmaceuticals, a dynamic and fast-growing radiopharmaceutical company, as the Director of Targeted Alpha Therapy Research. You will lead research projects in Targeted Alpha Therapy within the Telix portfolio, developing and implementing a long-term research theme plan to create platform capabilities and add value to Telix's proprietary products and pipeline.

Requirements

• PhD in a quantitative discipline (e.g. chemistry, biochemistry, pharmacology or biomedical engineering) or equivalent practical experience
• Relevant applied research experience in radiobiology, in vivo preclinical studies, radiochemistry, radiolabelled drug development and, ideally with specific knowledge of alpha-emitting radioisotopes
• At least 5 years or relevant R&D experience in the commercial environment with a solid understanding of the drug development process including preclinical studies, radiopharmacy/cGMP operations, clinical studies and regulatory processes
• Demonstrated knowledge of the TAT research field including relevant topics of alpha radiobiology, radiochemistries, isotopes (and their supply chain), chelators and targeting agents
• Proven prior experience managing complex technical research programs and successful 3rd party academic or commercial collaborations
• Recognised commercial acumen to guide corporate strategy in this area and prioritise projects according to future commercial outcomes

Responsibilities

• Lead the TAT research strategy in the company by developing and implementing a long-term research theme plan that will create platform capabilities and add value to Telix’s proprietary products and pipeline
• Drive research projects with a commercial mindset to evaluate, optimise and ultimately deliver meaningful outcomes that influence ongoing TAT projects and result in the addition of a panel of next generation alpha-emitting candidates to the pipeline portfolio
• Identify, lead and manage collaborations with strategic partners relating to radiochemistry and in vivo biological evaluation of Actinium-225, Astatine-211, Lead-212 and other alpha-emitting radioisotopes
• Ensure the delivery of ongoing and future projects relating to TAT by building capability through research partners, internal or externally-sourced resources
• Plan, implement and collate the experimental dataset required to evaluate either internally- or externally-generated technologies, prospective candidates or effective combinations of TAT technologies
• In conjunction with the chief scientist, ensure that the aims and progress of the Research Theme are communicated effectively and shared both internally and externally
• Support colleagues to enhance the development of existing assets by providing safety or efficacy data as well as technical input on the design and interpretation of clinical studies with TAT agents
• Maintain an awareness of the current literature, developments in the field and encouraging strategic partnerships with companies or academic groups to identify best industry practice and keep up with the state of the art
• Effectively manage program timelines, resources & expenditure and seek opportunities for grant applications as opportunities arise
• Provide technical support to other TLX projects to support the conduct of preclinical packages, clinical studies and regulatory filings

Benefits

• Competitive salaries
• Annual performance-based bonuses
• An equity-based incentive program
• Generous vacation
• Paid wellness days
• Support for learning and development